

# Pulmonary dysfunction in children with Duchenne muscular dystrophy may occur earlier than we thought – analysis using novel methodology based on z-scores

Eliza Wasilewska<sup>1</sup>, Sylwia Małgorzewicz<sup>2</sup>, Jarosław Meyer-Szary<sup>3</sup>, Karolina Sledzinska<sup>4</sup>, Marek B. Niedostryko<sup>1</sup>, Ewa Jassem<sup>1</sup>, Jolanta Wierzba<sup>4</sup>

<sup>1</sup>Department of Pulmonology and Allergology, Medical University of Gdańsk, Poland

<sup>2</sup>Department of Clinical Nutrition, Medical University of Gdańsk, Poland

<sup>3</sup>Department of Paediatric Cardiology and Congenital Heart Defects, Medical University of Gdańsk, Poland

<sup>4</sup>Department of General Nursery, Medical University of Gdańsk, Poland

**Submitted:** 8 February 2020; **Accepted:** 26 March 2020

**Online publication:** 21 March 2021

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms/119782>

Copyright © 2022 Termedia & Banach

**Corresponding author:**

Eliza Wasilewska  
Department of Pulmonology  
and Allergology  
Medical University of Gdańsk  
17 Smoluchowskiego St.  
80-214 Gdańsk, Poland  
E-mail: [ewasilewska@gumed.edu.pl](mailto:ewasilewska@gumed.edu.pl)

## Abstract

**Introduction:** Respiratory status is one of the main factors affecting the length of survival in patients with Duchenne muscular dystrophy (DMD) – the most common, severe, progressive muscular dystrophy. Aim of the study was (1) to assess pulmonary function in DMD patients using the z-score method and (2) to identify factors affecting it, irrespective of disease progression.

**Materials and methods:** We evaluated 55 boys (aged 5–18 years) with DMD. The spirometry was performed with: forced vital capacity (FVC), forced expiratory volume in 1 second (FEV<sub>1</sub>), peak expiratory flow (PEF) analysis as absolute values (in litres or litres/min), % predicted value (%pv) and z-scores (z). Information on the need of ventilation support, ambulatory status and steroid therapy was collected.

**Results:** 25 (45%) subjects were non-ambulatory, 38 (69%) used steroid therapy. Mean FVC[z]  $-2.4 \pm 2.2$ , FEV<sub>1</sub>[z]  $-2.0 \pm 1.9$ , PEF[z]  $-1.5 \pm 1.3$  values significantly decreased with age ( $r = -0.62/-0.65/-0.55$ ;  $p < 0.001$  respectively), after reaching the peak values in the range 9–12 or 6–9 years of age depending on the analysis method (absolute, %pv or z-score). The results fell below the normal range (z-score  $< -1.64$ ) at the age of 9.8/10.4/11.6 years and below 80%pv at 10.7/12.2/13.2 for FVC/FEV<sub>1</sub>/PEF, respectively. The pulmonary function test results were significantly lower in non-ambulant ( $p < 0.001$ ) and non-steroid patients ( $p < 0.02$ ).

**Conclusions:** Analysis of the pulmonary function test based on z-scores shows that deterioration of pulmonary function in DMD males may occur earlier than we thought when measured by %pv and absolute values. Early loss of ambulation, lack of steroids and delayed steroid therapy are risk factors for worse pulmonary outcomes. To confirm these findings, cohort longitudinal studies are necessary.

**Key words:** pulmonary function, pulmonary function testing (PFT), Duchenne muscular dystrophy, z-score.

## Introduction

Duchenne muscular dystrophy (DMD) is a severe, progressive, X-linked disorder affecting 1 in every 3500–5000 male births [1]. Mutations in

the dystrophin gene lead to an absence or defect in the protein product resulting in progressive muscle weakness and, in consequence, loss of ambulation, and cardiac and respiratory failure [2, 3]. The respiratory status is among the main factors determining the length of survival in DMD patients. Initially, patients have no difficulties in breathing or coughing and their pulmonary function test (PFT) results are within normal limits. The progression of the disease causes gradually increasing muscular weakness, which leads to respiratory complications [4–7]. Typically it is manifested by nocturnal hypoventilation, followed by day-time hypoxaemia, hypercapnia, and finally respiratory failure. Additionally, from the moment when the patient becomes non-ambulant (usually by the age of 10–12 years), and spends more time in a wheelchair in a forced sitting position, the impairment of lung function increases. This is particularly evident in patients who suffer from scoliosis [3, 8–10]. Historically, DMD results in death in the teens. Currently, through appropriate supportive treatment, the average life expectancy of a patient with DMD is approximately 30 years [6, 7]. A careful and systematic approach to patients' respiratory management may prolong survival [4, 11]; thus it is important to identify the moment of deterioration of pulmonary function in DMD patients.

The American Thoracic Society (ATS) recommends baseline pulmonary function assessment optimally between 4 and 6 years of age or before confinement to a wheelchair [10]. Patients should visit a paediatric pulmonologist twice yearly or while on mechanically assisted ventilation even every 3 months [5]. Although the Global Lung Initiative (GLI) and the European Respiratory Society (ERS) Taskforce Report recommend analysis of PFT based on the z-score, this method is still not used in DMD patients [12, 13]. Besides, large-scale, randomized controlled trials are rare in this field, so knowledge of the pulmonary status of DMD patients is often obtained from small clinical groups [14–16]. Therefore, subsequent studies of pulmonary function in DMD patients remain constantly up-to-date and important.

The aim of this study was (1) to assess pulmonary function in DMD patients using the z-score method and (2) to identify factors affecting it, irrespective of the disease progression.

## Material and methods

### Study design

In this prospective, single-centre, cross-sectional study, the pulmonary status of muscular dystrophy patients was evaluated. Boys visited the regional reference Rare Disease Centre in Gdansk for

the first time, between the years 2015 and 2017. The study was performed in compliance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). Approval for the study was obtained from the Committee of Ethics, no. NKBBN/105/2018, and informed written consent was obtained from all subjects. This study was funded by the Medical University of Gdańsk, Poland (Institutional Grant ST 554).

### Patients

Inclusion criteria were: (1) male aged 5–18 years, (2) confirmed diagnosis of DMD based on guidelines [6] – the presence of typical clinical symptoms, genetic testing, muscle biopsy results, (3) the ability to perform PFT.

Patients were evaluated according to the study protocol by a multidisciplinary team, including a paediatric pulmonologist. Interview, physical examination and spirometry were performed in all patients. Information on the need of ventilation support, ambulatory status, and steroid therapy (ST) (presence, type, dose, length and age of onset) was collected from interview and medical records. Anthropometric data – weight (a calibrated weighing chair – AXIS, model B 150 K, with accuracy to 50 g), height (in non-ambulatory patients as recumbent segmental length: head to hip, hip to knee, and knee to foot) – were measured according to the guidelines [6, 7].

### Pulmonary function test

Spirometry was performed using the calibrated, computerized spirometer Pneumo Screen, Jaeger, Germany, according to the ATS recommendations, by a certificated teenagers' physical therapist, experienced with children [10]. A minimum of three, and up to five, manoeuvres with maximum effort were attempted by each subject. The highest values of forced vital capacity (FVC), forced expiratory volume in 1 second ( $FEV_1$ ) expressed as litres [l], and peak expiratory flow (PEF) in litres per minute [l/min], from correct acceptable attempts, were included in the analysis. Corresponding % predicted value (%pv) and z-scores [z] for age, ethnicity, gender and height were calculated, based on the GAMLSS (Generalized Additive Model for Location, Scale and Shape) method in accordance with the 2012 GLI and ERS Taskforce Report, and recommendations using GLI-2012 Excel Sheet Calculator (Version 4, 25 May 2014) [13].

### Statistical analysis

Statistical analyses were performed using Wizard Pro 1.9.16 (Evan Miller, Chicago, IL). Data are given as mean ( $\pm$ SD) or median (min–max) depending on the distribution. Normality of the dis-

tribution was tested using the Shapiro-Wilk test. Student's *t*-test and the Mann-Whitney test were used as indicated. For multiple comparisons, proper ANOVA or Friedman tests were used. Categorical data were compared with the  $\chi^2$  test and  $\chi^2$  test for a trend (Cochran-Armitage). Pearson correlations, linear regression and multivariable linear models were additionally employed. To compare the rates of the disease progression between two groups we used the test for equality of two regression coefficients as recommended [17, 18]. Results having a *p*-value < 0.05 were considered statistically significant.

## Results

### Patients' characteristics

Out of 78 patients diagnosed previously with muscular dystrophy, 55 children met the inclusion criteria. Twenty-three patients were excluded for the following reasons: age below 5 years, mutation other than DMD (Becker muscular dystrophy), inability to perform PFT (9, 9, 5 males respectively). All patients were male Caucasians. Their characteristics are presented in Table I.

### Pulmonary function tests

PFT results are shown in Table II. Absolute FVC [l], FEV<sub>1</sub> [l], PEF [l/min] values increased with age, reaching peak numbers in children aged 9–12 years and then subsequently decreasing in older ones (Figures 1 A–C). Normalized FVC[z], FEV<sub>1</sub>[z], PEF[z] values start to decline earlier after reaching the highest z-score values in subjects aged 6–9 years (Figures 1 D, E).

While the correlation between %pv and z-score values was strong ( $R = 0.96$ ,  $R = 0.98$ ,  $R = 0.68$ ,  $p = 0.0001$  for FVC, FEV<sub>1</sub>, PEF respectively), analysis of the linear regressions for the whole sample revealed that the results fell below the normal range (z-score < -1.64) at the age of 9.8, 10.4, 11.6 years for FVC[z], FEV<sub>1</sub>[z], PEF[z], respectively, and fell below the normal range (value < 80%pv) at the age of 10.7, 12.2, 13.2 years for FVC%pv, FEV<sub>1</sub>%pv, PEF%pv, respectively.

There was a negative correlation between PFT described by z-scores of measured parameters and age: FVC[z] ( $r = -0.62$ ;  $p < 0.001$ ), FEV<sub>1</sub>[z] ( $r = -0.65$ ,  $p < 0.001$ ), and PEF[z] ( $r = -0.55$ ;  $p < 0.001$ ). A multiple linear regression was calculated to predict PFT results based on age. Significant regression equations were found for FVC[z], FEV<sub>1</sub>[z], PEF[z] (see Table III). Participants' predicted FVC[z] was 3.73, predicted FEV<sub>1</sub>[z] was 3.47 and PEF[z] was 1.57. Therefore annual z-score decline rates were 0.55, 0.49, 0.28 for FVC, FEV<sub>1</sub>, PEF respectively (Figures 1 D, E, regressions lines for the overall sample not depicted).

Consequently, the number of subjects with abnormal absolute and normative FVC, FEV<sub>1</sub>, PEF values increased with age ( $p = 0.001$ ,  $p = 0.002$ ,  $p = 0.048$ ; respectively, Cochran-Armitage test) (Figures 2 A–C).

All children older than 14.0 years had abnormal PFT with significant variability in the results. Interestingly, absolute FVC ranged from 0.6 l to 2.5 l (3 patients presented FVC under 1 l) (Figures 1 D, E).

### Pulmonary function test and ambulatory status

Patients who were able to walk on their own had significantly higher PFT results than non-ambulatory patients (Figure 3 A). The ambulatory transitional period is established between 10 and 14 years of age ( $n = 24$ ). In our study group 10 (42%) patients in this period were ambulant. Ambulatory patients in transitional age had significantly higher FVC[z] and FEV<sub>1</sub>[z] ( $p < 0.05$  for both variables), but not PEF[z] ( $p = 0.190$ ), in comparison to the non-ambulatory patients (Figure 3 B). Similar results were obtained for FVC %pv, FEV<sub>1</sub> %pv, PEF %pv: 87.3 vs. 57.7; 94.5 vs. 63.6 and 79.7 vs. 60.7, respectively ( $p = 0.0001$ ).

**Table I.** Anthropometric and baseline characteristics of subjects


Variables	Value
Anthropometric	
Age [years]	10.6 ± 2.9 (5–18)
Weight [kg]	36.0 ± 3.9 (17.5–94.0)
Height [cm]	133.0 ± 4.2 (108–170)
BMI [kg/m <sup>2</sup> ]	20.2 ± 5.3 (19.2–30.3)
Stage of disease, <i>n</i> (%)	
Ambulatory/Non-ambulatory	25/30
Ambulatory/Non-ambulatory with steroid therapy	14/25
Non-invasive ventilation	1 (2)
Steroid therapy	
ST, <i>n</i> (%)	38 (69%)
Duration of ST [years]	3.4 ± 1.2 (0.5–13.1)
Age at the beginning ST [years]	6.2 ± 0.3 (3–14)
Prednisone/deflazacort, <i>n</i>	22/16
Mean dose [mg/kg body mass/day]:	
Prednisone	0.28 ± 0.06 (0.05–0.45)
Deflazacort	0.40 ± 0.09 (0.05–0.65)

Anthropometric and duration, start, doses of ST are shown as mean ± SD [range] values. ST – steroid therapy, BMI – body mass index.

**Table II.** Descriptive statistics [mean ±SD (range)] of spirometric variables by age group

Variables	Age group [years]					
	5–6, n = 6	6–9, n = 14	9–12, n = 16	12–15, n = 10	15–18, n = 9	All patients, n = 55
FVC [l]	0.96 ±0.21 (0.67–1.29)	1.40 ±0.35 (0.73–1.99)	1.90 ±0.39 (1.40–2.52)	1.70 ±0.61 (0.85–2.83)	1.63 ±0.71 (0.64–2.47)	1.59 ±0.55 (0.64–2.83)
FVC %pv	74.10 ±17.40 (53.10–99.20)	88.80 ±25.70 (39.60–122.00)	84.90 ±14.54 (61.32–113.10)	58.24 ±25.89 (29.00–104.10)	44.34 ±16.11 (16.87–67.43)	73.87 ±27.01 (16.80–122.01)
FVC z-score	-2.00 ±1.18 (-3.36 to -0.29)	-0.94 ±1.94 (-5.12–1.37)	-1.30 ±1.21 (-3.42–1.08)	-3.82 ±2.10 (-6.64 to -0.41)	-5.33 ±1.58 (-7.65 to -3.29)	-2.40 ±2.30 (-7.65–1.37)
FEV <sub>1</sub> [l]	0.91 ±0.21 (0.66–1.28)	1.28 ±0.29 (0.72–1.67)	1.69 ±0.33 (1.29–2.32)	1.59 ±0.53 (0.84–2.58)	1.47 ±0.64 (0.60–2.38)	1.45 ±0.47 (0.60–2.58)
FEV <sub>1</sub> %pv	82.50 ±19.90 (61.00–116.30)	91.65 ±26.11 (40.72–136.41)	91.83 ±14.53 (69.40–117.21)	65.23 ±26.67 (34.76–105.91)	47.72 ±20.50 (19.12–78.40)	80.57 ±28.09 (19.10–136.43)
FEV <sub>1</sub> z-score	-1.76 ±1.24 (-2.99–0.43)	-0.71 ±1.77 (-4.56–1.55)	-1.10 ±1.17 (-2.83–1.19)	-3.14 ±1.83 (-5.60 to -0.63)	-4.65 ±1.40 (-6.63 to -2.65)	-2.02 ±2.05 (-6.63–1.55)
PEF [l/min]	2.04 ±0.74 (1.37–3.30)	2.69 ±0.57 (1.56–3.75)	3.20 ±0.49 (2.39–4.38)	3.18 ±0.93 (1.98–4.43)	3.59 ±1.06 (2.19–4.92)	2.99 ±0.83 (1.37–4.92)
PEF %pv	73.30 ±26.50 (51.60–118.70)	84.40 ±20.22 (42.76–124.23)	74.89 ±10.41 (60.10–91.76)	60.60 ±25.23 (33.01–108.74)	53.80 ±16.89 (38.92–74.33)	71.11 ±21.45 (33.10–124.21)
PEF z-score	-1.31 ±1.30 (-2.37–0.91)	-0.71 ±1.11 (-2.81–1.18)	-1.22 ±0.52 (-1.96 to -0.40)	-1.94 ±1.24 (-3.27–0.42)	-2.95 ±1.64 (-5.20 to -0.99)	-1.53 ±1.33 (-5.20–1.18)

FVC – forced vital capacity, FEV<sub>1</sub> – forced expiratory flow in 1 second, PEF – peak expiratory flow, age groups given in left-closed, right-open intervals – that is, including the left and excluding the right boundaries.



**Figure 1.** Comparison of pulmonary function testing (PFT) measured as absolute values (l or l/min, top panel A–C)





Figure 1.Cont. Normalized as z-scores (panel D–F) and % predicted volume (panel G–I) by age

**Table III.** Multivariate regression models predicting the pulmonary function testing (PFT)

Variables	FVC [z]		FEV <sub>1</sub> [z]		PEF [z]	
	Coefficient	p-value	Coefficient	p-value	Coefficient	p-value
Age [years]	-0.551	< 0.001	-0.303	< 0.001	-0.166	< 0.001
Ambulation	-1.188	0.004	1.233	< 0.001	0.619	0.021
Steroids, yes/no	1.525	< 0.001	1.125	0.008	-0.13	0.410
Steroid therapy duration [years]	0.334	0.036	0.340	0.021	0.334	0.072
Constant	3.400	0.091	3.822	0.043	2.401	0.110
R <sup>2</sup>	0.805	< 0.001	0.784	< 0.001	0.747	< 0.001

FVC – forced vital capacity, FEV<sub>1</sub> – forced expiratory flow in 1 second, PEF – peak expiratory flow.




**Figure 2.** Number of patients with normal and abnormal results of pulmonary function testing (PFT) z-score by age group (n given inside the bars)

### Pulmonary function test and steroid therapy


Patients treated with steroid therapy (on-ST) presented significantly higher values of FVC %pv (81.1 ± 27.1 vs. 61.1 ± 22.2, *p* = 0.002), FEV<sub>1</sub> %pv (87.1 ± 27.8 vs. 69.1 ± 25.1, *p* = 0.02), PEF %pv (74.5 ± 21.8 vs. 65.1 ± 20.1, *p* = 0.11) and also FVC[z] (-1.7 ± 2.3 vs. -3.4 ± 2.0, *p* = 0.005), FEV<sub>1</sub>[z] (-1.5 ± 2.0 vs. -2.8 ± 1.9, *p* = 0.016), but not PEF[z] (-1.4 ± 1.4 vs. -1.8 ± 1.1, *p* = 0.257), than patients without steroid therapy (non-ST). This difference did not reach statistical significance within age subgroups (Figures 4 A–C), probably as a result of small sample sizes.

Analysing the possible effect of the type of steroid used (deflazacort vs. prednisone) we did not find any significant difference in FVC[z] (-1.4 ± 2.1 vs. -2.4 ± 2.5, *p* = 0.189), FEV<sub>1</sub>[z] (-1.2 ± 1.9 vs. -2.1 ± 2.2, *p* = 0.246), PEF[z] (-1.3 ± 1.3 vs. -1.6 ± 1.6, *p* = 0.478) or in the proportion of ambulant and non-ambulant patients (56% vs. 45%, *p* = 0.511). Similarly, there were no significant differences for FVC %pv (75.1 vs. 84.9, *p* = 0.125), FEV<sub>1</sub> %pv (80.9 vs. 91.7, *p* = 0.253), PEF %pv (71.7 vs. 76.5, *p* = 0.510).

A positive correlation between use of steroids and FVC[z], and FEV<sub>1</sub>[z] (Spearman *R* = 0.55; *p* < 0.05 for both variables) and PEF (Spearman *R* = 0.31; *p* < 0.05) was noted. Also, we observed



**Figure 3.** Pulmonary function test (normalized value) in ambulatory and non-ambulatory groups in all patients and in transitional subgroup of 10–14 years



**Figure 4.** Mean normalized pulmonary function testing (PFT) values by age group and current steroid treatment (ST) status

a positive correlation between use of steroids and FVC %pv, FEV<sub>1</sub> %pv (Spearman  $R = 0.36$  for both variables;  $p < 0.05$ ), but not for PEF.

Additionally, the duration of ST had a positive effect on PFT outcomes correcting for age (multiple linear model; Table III).

To determine the effect of ST on the disease progression rate we fitted linear regression mod-

els separately for the on-ST and non-ST patients. The predicted levels of FVC[z], FEV<sub>1</sub>[z] and PEF[z] are presented in Table IV.

Comparing the slopes of the annual decline rate of PFT, they were similar in both on-ST and non-ST subgroups (Figure 4), for FVC[z] (–0.55 and –0.48;  $p = 0.637$ ), FEV<sub>1</sub>[z] (–0.48 and –0.45;  $p = 0.863$ ), PEF[z] (–0.25 and –0.29 respectively;  $p = 0.660$ ).

**Table IV.** Predicted statistically significant ( $p < 0.001$ ) levels of FVC[z], FEV<sub>1</sub>[z] and PEF[z] by age in patients treated with steroid therapy (ST) and patients without steroid therapy (non-ST)

Parameters	ST patients	Non-ST patients
FVC [z]	4.23	2.13
FEV <sub>1</sub> [z]	3.68	2.50
PEF [z]	1.80	1.14

Thus, we found no significant differences in the rate of PFT decline between the two subgroups.

However, the regression lines are shifted and intersect the threshold for a lower level of normal (z-score  $< -1.64$ ) at different ages for on-ST vs non-ST patients: FVC (10.7 vs. 7.9), FEV<sub>1</sub> (11.2 vs. 9.2 years of age respectively). This could be interpreted as 3 years of advantage for FVC and 2 years of advantage for FEV<sub>1</sub> of the treated vs untreated patients. The results presented as %pv showed slower progression with steroid treatment, and the regression lines shifted the threshold for a lower level of normal ( $< 80\%$ pv) later than presented in the z-score (on-ST vs. non -ST patients: FVC 11.0 vs. 8.1, FEV<sub>1</sub> 11.5 vs. 9.6 years of age respectively, Figures 1 G–J).

#### Multivariable regression model

Finally, including all the identified risk factors (patient age, ambulatory status, ST) we calculated multiple-linear regression models to predict FVC[z], FEV<sub>1</sub>[z], PEF[z] for DMD patients. Age was considered a continuous variable, ambulatory status and ST were coded 0 = no, 1 = yes. FVC[z] and FEV<sub>1</sub>[z] were significantly dependent on age, ambulatory status and ST, PEF[z] only on age and ambulatory status (Table III). Specifically, FVC[z], FEV<sub>1</sub>[z], PEF[z] decreased with age by 0.359, 0.303, 0.166 respectively annually but were 1.188, 1.233, 1.619 higher if the patient was ambulant. ST influenced FVC[z] and FEV<sub>1</sub>[z], by 1.525 and 1.125 respectively.

#### Discussion

Our study provides an insight into the respiratory system condition assessed by PFT in 5–18-year-old, male Caucasian DMD patients in different stages of the disease, addressing for the first time the reference centre in northern Poland. More than half (55%) were non-ambulatory, and the majority (69%) were treated with glucocorticoids. We have used state-of-the-art methodology to interpret PFT results in children, that is calculating z-scores based on the GAMLSS method. This method has been recently recommended by the GLI 2012 and ERS, as it is considered to be superior to the still commonly used method of express-

ing the results as a percentage of the predicted value [10, 13].

#### Pulmonary function parameters in different stages of the disease

The most important finding of our study was that, using the GAMLSS method, we determined the difference in time of PFT peak between absolute values, percentage of predicted volume and z-score values. Noticeably, the measured parameters still increase until the age of 9–12 years, but with normalized data it becomes apparent that pulmonary status deceptively starts to decline much earlier – from the age of 6–9 years after reaching the highest z-score values. While the correlation between %pv and z-score values was strong, our analysis showed that the z-score could predict a faster decline of PFT value than %pv in patients with DMD. It is an interesting finding that may change everyday practice, focusing the clinician’s attention on z-score values of PFT results. Earlier pulmonary function decline should lead to earlier introduction of respiratory physiotherapy in DMD patients. It also means that their pulmonary capacity never develops to its full potential as in healthy peers. The observation above further underlines the necessity to use normalized data in interpretation of the results in children as they account for the effects of development (growth) and body size among others.

Generally, all PFT values significantly decrease with age after reaching the peak values, which is consistent with the natural history of pulmonary function in DMD patients described in two prospective studies of a longitudinal observational cohort: the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) and an Institutional Review Board approved United Dystrophinopathy Project (UDP) cohort study [19, 20].

Interestingly, out of all analysed z-score parameters, FVC started to fall in the earliest age, and faster than others. This indicates that the FVC is a good and sensitive parameter for monitoring the progression of the disease, which is confirmed by the updated guidelines [5]. Also, the decline in FVC is historically the best validated pulmonary function predictor of mortality in DMD patients [10, 21].

The next interesting fact is that all children over the age of 14.0 years had FVC values below the normal range for age, but at the same time, there was significant variability in the measured FVC in litres. Phillips *et al.* evaluated a threshold of FVC of 1 l as a predictor of unfavourable outcome (5-year survival – 8%) [21]. Similar lung function deterioration rate and course of the disease have been reported in the literature [22–27]. To validate these findings, we need to recruit more patients

and continue with a longitudinal study.

### Effect of loss of ambulation on PFT

Per subgroup analysis we concluded that patients who were not able to walk on their own had lower PFT results than ambulatory patients at the same age. The moment of loss of ambulation coincides with the onset of decline of measured FVC and FEV<sub>1</sub>. We are unsure whether to treat it as a consequence of the natural course of the disease or as a complication of immobilization together with progressive scoliosis, which may worsen conditions for ventilation by itself. Such conclusions were drawn by some authors previously [20, 28, 29]. Moreover, Philips *et al.* concluded that a reduction in FVC to less than 1 l increased the risk of a faster transition to a wheelchair and also predicted median survival length of 3.1 years [21].

### Pulmonary function parameters and ST

The results of our study indicated that steroids positively influence pulmonary outcome; steroid treatment delays, but does not prevent, the progression of the disease. Independently of steroid regimens (prednisone or deflazacort), we found better PFT results, both absolute and normalized. The onset of pulmonary function loss was delayed from 2 to 3 years in patients on ST compared to non-ST.

Our PFT results performed in the Polish cohort are similar to other authors' findings. Two randomized controlled trial studies described the impact of ST on pulmonary function assessed by FVC [16, 30]. Griggs *et al.* reported an improvement in FVC of about 0.16 l in subjects treated with prednisone (0.3 mg/kg/day) for six months compared to the placebo group [16]. Mendell *et al.* evaluated treatment with prednisone 1.5 mg/kg/day versus placebo for six months, finding a mean improvement in FVC in the treatment group, similarly to the Griggs study (0.14 l more than in the placebo group) [30]. Similar results are available from non-randomized cohort studies which showed improvement of FVC in patients on ST [31–34].

Although a Cochrane review confirmed the positive effect of steroids on pulmonary function, administration of ST in DMD is still controversial due to multiple adverse reactions associated with chronic uptake [14, 15, 35, 36]. Further, the optimal standard regimen is still under discussion; there are questions about the frequency of administration and the optimum dose – adequate to be efficient, but at the same time not provoking significant side-effects. Bushby *et al.* recommended starting the treatment during the plateau phase – while there is no longer progress in motor skills, but prior to the decline, as described by medical history and exercise testing [4]. So far it

is proven that 0.75 mg/kg of prednisone daily or the deflazacort equivalent of 0.9 mg/kg stabilizes strength in DMD [37]. In our study the data come from a first-time visit to our centre – consequently, the cohort is heterogenous in the prior approach to the ST. Also, frequently the prior follow-up intervals were longer than recommended and thus the ST doses were not updated adequately for growth. Surprisingly, despite that fact, we were able to detect statistically significant effects of the treatment on the PFT, delaying pulmonary function decrease by 2–3 years.

Despite the limitation of the study in the form of a relatively small sample size, our results show the benefits of using normalized values (z-score) for parameters determining pulmonary function. Additionally, our study is the first to analyse pulmonary function of the DMD population in northern Poland. Furthermore, according to our best knowledge, this is also the first study of pulmonary function in DMD patients to employ the GLI 2012 guidelines and recommended normative values of z-scores and GAMLSS methodology.

### Clinical implications

Deterioration of respiratory function in DMD boys may occur even earlier than previously thought. Patients, their carers and health care providers should be informed about the necessity of frequent assessment of the respiratory system. PFT results should be interpreted also as z-score values. Better respiratory system evaluation may lead to earlier medical intervention, resulting in improved quality of life for DMD patients.

### Conclusions

The results of the current study show the difference in the time of peak of PFT between values measured as absolute, % predicted and z-scores, which decrease with the progression of the disease. Interpretation of PFT results based on the z-score, reflects changes in pulmonary function earlier and more specifically than the other values. As a consequence, appropriate physiotherapy will be applied sooner. This is especially important for patients with risk factors for worse pulmonary outcomes, which were: early loss of ambulation and lack of or delayed steroid therapy.

### Conflict of interest

The authors declare no conflict of interest.

### References

1. Emery AE. Population frequencies of inherited neuromuscular diseases – a world survey. *Neuromuscul Disord* 1991; 1: 19-29.

2. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell* 1987; 51: 919-28.
3. Roberto R, Fritz A, Hagar Y, Boice B, Skalsky A, Hwang H, et al. The natural history of cardiac and pulmonary function decline in patients with Duchenne muscular dystrophy. *Spine* 2011; 36: E1009-17. doi: 10.1097/BRS.0b013e3181fea1ed.
4. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol* 2010; 9: 177-89.
5. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol* 2018; 17: 347-61.
6. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol* 2018; 17: 251-67.
7. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. *Lancet Neurol* 2010; 9: 77-93.
8. Kurz LT, Mubarak SJ, Schultz P, Park SM, Leach J. Correlation of scoliosis and pulmonary function in Duchenne muscular dystrophy. *J Pediatr Orthop* 1983; 3: 347-53.
9. Bach JR. Update and perspective on noninvasive respiratory muscle aids. Part 2: the expiratory aids. *Chest* 1994; 105: 1538-44.
10. Finder JD. A 2009 perspective on the 2004 American Thoracic Society statement, "respiratory care of the patient with Duchenne muscular dystrophy." *Pediatrics* 2009; 123 Suppl 4: S239-241.
11. Toussaint M, Chatwin M, Soudon P. Mechanical ventilation in Duchenne patients with chronic respiratory insufficiency: clinical implications of 20 years published experience. *Chron Respir Dis* 2007; 4: 167-77.
12. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J* 2005; 26: 319-38.
13. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; 40: 1324-43.
14. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. *Cochrane Database Syst Rev* 2004; 2: CD003725. doi: 10.1002/14651858.CD003725.pub3.
15. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, et al. Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. *Arch Neurol* 1987; 44: 812-7.
16. Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. *Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol* 1991; 48: 383-8.
17. Clogg CC, Petkova E, Haritou A. Statistical methods for comparing regression coefficients between models. *American Journal of Sociology* 1995; 100: 1261-93.
18. Paternoster R, Brame R, Mazerolle P, Piquero A. Using the correct statistical test for the equality regression coefficients. *Criminology* 1998; 36: 859-66.
19. Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arieta A, et al. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. *Muscle Nerve* 2013; 48: 55-67.
20. Mayer OH, Finkel RS, Rummey C, Benton MJ, Glanzman AM, Flickinger J, et al. Characterization of pulmonary function in Duchenne Muscular Dystrophy. *Pediatr Pulmonol* 2015; 50: 487-94.
21. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. *Am J Respir Crit Care Med* 2001; 164: 2191-4.
22. Humbertclaude V, Hamroun D, Bezzou K, Bérard C, Boesflug-Tanguy O, Bommelaer C, et al. Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. *Eur J Paediatr Neurol* 2012; 16: 149-60.
23. Rideau Y, Jankowski LW, Grellet J. Respiratory function in the muscular dystrophies. *Muscle Nerve* 1981; 4: 155-64.
24. Gayraud J, Ramonatxo M, Rivier F, Humberclaude V, Petrof B, Matecki S. Ventilatory parameters and maximal respiratory pressure changes with age in Duchenne muscular dystrophy patients. *Pediatr Pulmonol* 2010; 45: 552-9.
25. LoMauro A, D'Angelo MG, Aliverti A. Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options. *Ther Clin Risk Manag* 2015; 11: 1475-88.
26. Khirani S, Ramirez A, Aubertin G, Boulé M, Chemouny C, Forin V, et al. Respiratory muscle decline in Duchenne muscular dystrophy. *Pediatr Pulmonol* 2014; 49: 473-81.
27. Tangsrud S, Petersen IL, Lødrup Carlsen KC, Carlsen KH. Lung function in children with Duchenne's muscular dystrophy. *Respir Med* 2001; 95: 898-903.
28. Hsu JD. The development of current approaches to the management of spinal deformity for patients with neuromuscular disease. *Semin Neurol* 1995; 15: 24-8.
29. Shapiro F, Zurakowski D, Bui T, Darras BT. Progression of spinal deformity in wheelchair-dependent patients with Duchenne muscular dystrophy who are not treated with steroids: coronal plane (scoliosis) and sagittal plane (kyphosis, lordosis) deformity. *Bone Joint J* 2014; 96-B: 100-5. doi: 10.1302/0301-620X.96B1.32117.
30. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. *N Engl J Med* 1989; 320: 1592-7.
31. Biggar WD, Politano L, Harris VA, Passamano L, Vajsar J, Alman B, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. *Neuromuscul Disord* 2004; 14: 476-82.
32. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. *J Pediatr* 2001; 138: 45-50.
33. Biggar WD. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. *Neuromuscul Disord* 2006; 16: 249-55.
34. Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients

- with Duchenne muscular dystrophy. *Am J Cardiol* 2003; 91: 769-72.
35. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. *Cochrane Database Syst Rev* 2016; 5: CD003725. doi: 10.1002/14651858.CD003725.pub4.
  36. Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2016; 86: 465-72.
  37. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. *Muscle Nerve* 2000; 23: 1344-7.